The primary objective of the trial is to determine the Maximum Tolerated Dose (MTD), Dose-Limiting Toxicity (DLT), recommended dose and dosing schedule and safety profile of REOLYSIN(R) when administered in combination with carboplatin and paclitaxel.
What does MTD stand for?
MTD stands for Maximum Tolerated Dose
This definition appears very frequently and is found in the following Acronym Finder categories:
- Science, medicine, engineering, etc.
See other definitions of MTD
We have 185 other meanings of MTD in our Acronym Attic
- Makaveli The Don (Tupac Shakur)
- Malignant Teratoma Differentiated (cancer)
- Maneuvering Technology Demonstrator
- Manufacturing Technology Development
- Manufacturing Technology Division
- Marine Technology Directorate Ltd. (United Kingdom)
- Materiel Test Directorate
- Maximum Theoretical Density
- Maximum Tolerable Downtime (business security)
- Maximum Transmission Distance
- Mean Texture Depth
- Mean Therapeutic Dose
- Media Technology Drivers
- Memory Technology Device
- Memory Technology Driver
- Memory-Enhanced Test Driver
- Metal Trades Department (American Federation of Labor-Congress of Industrial Organizations; Washington, DC)
- Methadone (drug screening)
- Metric Tonnes Per Day
Samples in periodicals archive:
Description of other effects of LGD1057 awaits accrual of additional patients and determination of the maximum tolerated dose in this ongoing study.
Recent animal trials with aldoxorubicin-doxorubicin combination showed favorable results in ovarian and pancreatic cancers LOS ANGELES -- CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical company specializing in oncology, today announced the initiation of a Phase 1b clinical trial to determine the maximum tolerated dose and to evaluate preliminary efficacy of aldoxorubicin (formerly INNO-206) administered in combination with the commonly used chemotherapeutic agent doxorubicin in patients with advanced solid tumors who have failed other therapies.
Conducted by Kosan and Roche as part of a global partnership to jointly develop and commercialize KOS-862, the Phase I trials were designed to determine the maximum tolerated dose, toxicity profile, pharmacokinetics and pharmacodynamics of intravenous KOS-862.
The maximum tolerated dose in this study also was determined by diminished blood platelet levels.
A primary objective of the trial is to determine the maximum tolerated dose (MTD) of huN901-DM1 in multiple myeloma patients with this dosing schedule.
Another phase I study showed SGN-40 induces antitumor activity, is well-tolerated and a maximum tolerated dose has not been reached in patients with relapsed multiple myeloma.
This study was primarily designed to evaluate the safety of MK-0457 given as a 5-day continuous infusion, to determine maximum tolerated dose and dose-limiting toxicities and to assess pharmacokinetics and pharmacodynamics.